LTGO Analyst Ratings
Latigo Biotherapeutics Inc. (LTGO) operates in the Healthcare sector, specifically the Medical - Pharmaceuticals industry, with a market capitalization near $945.0M, listed on NASDAQ, employing roughly 66 people, carrying a beta of 0.00 to the broader market. Latigo Biotherapeutics, Inc. Led by Nima Farzan, public since 2026-08-07.
Analyst Ratings
In the October 2026 monthly count, 4 analysts rated LTGO: 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell.
Price Targets
- Average Target
- $52.25
- Median Target
- $50.00
- High
- $73.00
- Low
- $36.00
- Targets Published, Last 12 Months
- 4
Recent Price Targets
The 4 most recent of at least 4 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Sep 1, 2026 | Jefferies | Akash Tewari | $50.00 | $22.02 |
| Sep 1, 2026 | Leerink Partners | Not named | $36.00 | $22.02 |
| Sep 1, 2026 | Guggenheim | Yatin Suneja | $50.00 | $22.02 |
| Sep 1, 2026 | Goldman Sachs | Not named | $73.00 | $22.02 |
How to Read LTGO Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked LTGO analyst ratings questions
- What is the LTGO consensus price target?
- As of the latest aggregator update, Latigo Biotherapeutics Inc. (LTGO) carries a consensus 12-month price target of $52.25. Target ranges run from a low of $36.00 to a high of $73.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on LTGO?
- In the October 2026 monthly count, 4 analysts rated LTGO, and the distribution tilts to the Buy side: 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has LTGO seen?
- Recent ratings actions for LTGO are not currently in the snapshot.
- How do analyst targets affect LTGO options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.